Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations

NCT04293562 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT04293562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04293562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Recruiting
Start date
July 21, 2020
Completion date
June 30, 2029
Enrollment
1,400 (estimated)
Sites
206

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia